Pentaglobin is a medication used in this clinical trial. It is an immunoglobulin preparation that is administered to patients who have undergone a procedure to control an infection source in the abdomen, specifically in cases of peritonitis. The goal of using Pentaglobin in this study is to help improve the function of multiple organs, such as the lungs, heart, kidneys, liver, and blood, by reducing the severity of organ failure over a period of seven days after the infection source has been controlled.

Secondary Peritonitis – This condition occurs when the lining of the abdominal cavity, known as the peritoneum, becomes inflamed due to an infection that spreads from another part of the body. It often results from a rupture in the abdominal organs, such as the appendix or intestines, leading to the leakage of bacteria or other harmful substances into the peritoneal cavity. The inflammation can cause severe abdominal pain, tenderness, and swelling. As the condition progresses, it may lead to the formation of abscesses and can affect the function of nearby organs. If not managed, the infection can spread, leading to more severe complications.

Sepsis – This is a serious medical condition that arises when the body’s response to an infection causes widespread inflammation. It can begin with an infection in any part of the body, such as the lungs, urinary tract, or skin, and can lead to systemic inflammation. As sepsis progresses, it can cause a drop in blood pressure, leading to poor blood flow to vital organs. This can result in organ dysfunction or failure if not addressed promptly. The condition can escalate quickly, requiring immediate medical attention to prevent further complications.